Detalhe da pesquisa
1.
Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy.
World J Urol
; 41(1): 43-50, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36527468
2.
Current status and future perspective of immunotherapy for renal cell carcinoma.
Int J Clin Oncol
; 2023 Dec 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38108981
3.
Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men.
Int J Urol
; 30(7): 600-604, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37078488
4.
Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study.
Int J Urol
; 30(11): 977-984, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37434386
5.
Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy.
Int J Urol
; 30(4): 340-346, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36478611
6.
Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
Anticancer Drugs
; 33(1): e541-e547, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34387597
7.
Validation of models predicting lymph node involvement probability in patients with prostate cancer.
Int J Urol
; 29(5): 428-434, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35102610
8.
Impact of nerve sparing in robot-assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence.
Int J Urol
; 29(8): 824-829, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35411637
9.
Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer.
Int J Urol
; 29(10): 1155-1162, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35717139
10.
Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
Cancer Invest
; 39(3): 251-256, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33393849
11.
Prognostic impact of prior local therapy in castration-resistant prostate cancer.
Jpn J Clin Oncol
; 51(7): 1142-1148, 2021 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33621330
12.
Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
Int J Urol
; 27(12): 1109-1115, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32929792
13.
Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer.
Andrologia
; 51(9): e13354, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31230398
14.
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
Clin Genitourin Cancer
; : 102094, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38714434
15.
Validation of user-friendly models predicting extracapsular extension in prostate cancer patients.
Asian J Urol
; 10(1): 81-88, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36721693
16.
Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation.
J Robot Surg
; 17(6): 2721-2728, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37634216
17.
Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
Anticancer Res
; 43(9): 4249-4254, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37648320
18.
Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide.
JMA J
; 5(4): 491-497, 2022 Oct 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36407065
19.
Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors.
JMA J
; 5(1): 83-90, 2022 Jan 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35224264
20.
Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.
Urol Oncol
; 39(6): 365.e1-365.e7, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33077351